Home
Scholarly Works
2025 Clinical Practice Guideline Update by the...
Journal article

2025 Clinical Practice Guideline Update by the Infectious Diseases Society of America on the Treatment and Management of COVID-19: Vilobelimab

Abstract

This article provides a focused update to the clinical practice guideline on the treatment and management of patients with coronavirus disease 2019 (COVID-19), developed by the Infectious Diseases Society of America. The guideline panel presents a recommendation on the use of vilobelimab in hospitalized adults with critical COVID-19. The recommendation is based on evidence derived from a systematic literature review and adheres to a standardized methodology for rating the certainty of evidence and strength of recommendation according to the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach.

Authors

Nadig N; Bhimraj A; Cawcutt K; Chiotos K; Dzierba AL; Kim AY; Martin GS; Pearson JC; Shumaker AH; Baden LR

Journal

Clinical Infectious Diseases, Vol. 81, No. Supplement_3, pp. i13–i16

Publisher

Oxford University Press (OUP)

Publication Date

January 16, 2026

DOI

10.1093/cid/ciaf235

ISSN

1058-4838

Contact the Experts team